Revolution Medicines
D

RVMD

Revolution Medicines balance sheet 2017–2026

Revolution Medicines had 3.65B USD in cash and short-term investments on 30 September 2026, against total debt of 639.10M USD: net cash of 3.01B USD.

Total assets Total liabilities Shareholders' equity

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
Latest
Q3 FY2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
Cash and equivalents
615.91M383.75M543.06M696.15M161.41M108.50M104.27M16.66M69.59M9.08M
Short-term investments
3.04B1.64B1.75B1.16B483.53M468.56M336.47M106.10M0.000.00
3.65B2.03B2.29B1.85B644.94M577.05M440.74M122.76M69.59M9.08M
Cash growth
+89.04%-11.52%+23.55%+187.31%+11.76%+30.93%+259.03%+76.41%+666.45%—
Receivables
230.72M0.000.001.25M4.67M5.93M6.39M8.74M7.30M0.00
Inventory
11.02M0.000.000.000.000.000.000.006.60M0.00
Other current assets
83.57M49.36M38.33M25.07M10.57M0.000.000.006.60M0.00
Total current assets
3.98B2.08B2.33B1.88B660.19M589.77M454.12M133.98M85.43M9.44M
Property, plant and equipment
160.02M165.28M141.82M100.01M73.74M71.24M36.34M7.15M6.87M5.25M
Long-term investments
0.000.000.000.000.000.000.000.000.000.00
Goodwill and intangibles
70.08M70.41M71.28M72.35M73.42M74.48M75.55M76.62M77.69M—
Goodwill
14.61M14.61M14.61M14.61M14.61M14.61M14.61M14.61M14.61M—
Intangible assets
55.47M55.80M56.67M57.74M58.81M59.88M60.95M62.01M63.08M—
Other non-current assets
96.71M43.79M17.57M10.06M4.59M2.50M1.39M2.78M593.00K383.00K
Total assets
4.30B2.35B2.56B2.06B811.93M737.99M567.40M220.53M170.59M15.08M
Accounts payable
100.66M64.62M54.43M61.79M21.31M14.06M12.61M11.40M5.24M3.35M
Deferred revenue
0.000.000.000.004.46M12.36M12.11M17.12M16.83M0.00
Short-term debt
0.000.000.000.000.000.000.000.000.000.00
Other current liabilities
0.0066.05M31.36M27.51M13.79M10.16M7.83M5.73M6.06M2.55M
Total current liabilities
475.67M290.42M163.91M143.85M61.98M60.35M47.18M43.05M30.55M7.60M
Long-term debt
487.88M142.23M0.000.000.000.000.000.000.000.00
Other non-current liabilities
796.62M288.20M3.86M7.97M301.00K634.00K632.00K2.40M2.77M2.95M
Lease obligations, current
9.38M16.47M12.87M7.37M6.77M6.21M3.67M0.00147.00K0.00
Lease obligations, long-term
141.84M0.00122.97M80.58M57.43M60.42M28.99M0.000.000.00
Total liabilities
1.90B723.21M293.10M235.51M126.74M135.42M92.73M67.99M73.93M10.55M
Common stock and paid-in capital
22.00K19.00K18.00K16.00K9.00K8.00K7.00K0.000.000.00
Retained earnings
-4.37B-2.87B-1.74B-1.14B-701.34M-452.64M-265.55M-157.39M-109.72M-67.93M
Accumulated other comprehensive income
-14.67M3.24M1.32M544.00K-1.78M-376.00K116.00K74.00K0.000.00
Shareholders' equity
2.40B1.63B2.27B1.83B685.19M602.57M474.68M152.54M96.66M4.53M
Minority interest
0.000.000.000.000.000.000.000.000.000.00
639.10M158.70M135.84M87.94M64.21M66.63M32.66M0.00147.00K0.00
Net cash
3.01B1.87B2.15B1.77B580.74M510.42M408.08M122.76M69.44M9.08M
Working capital
3.50B1.78B2.16B1.74B598.20M529.42M406.95M90.93M54.88M1.84M
Book value per share
11.178.5813.5016.148.508.287.134.182.650.12
Tangible book value
2.33B1.56B2.19B1.75B611.77M528.08M399.12M75.91M18.97M4.53M
Tangible book value per share
10.858.2113.0815.507.597.255.992.080.520.12
Current ratio
8.367.1414.2013.0610.659.779.633.112.801.24
Debt to equity
0.270.100.060.050.090.110.070.000.000.00

Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.

Common questions about Revolution Medicines's cash and debt

Source: Financial Modeling PrepVerified against SEC filings